Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 15/20 | 0.60 |
| ▸ | FGFR1 | P11362 | 10/20 | 0.60 |
| ▸ | FLT1 | P17948 | 10/20 | 0.60 |
| ▸ | EGFR | P00533 | 8/20 | 0.60 |
| ▸ | FLT4 | P35916 | 7/20 | 0.60 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.45 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.41 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7738590 | 1.00 | KDR (0.60) | KDRFGFR1FLT1EGFRFLT4 | |
| SCHEMBL5462230 | 0.84 | KDR (0.44) | KDRFGFR1FLT1EGFRFLT4 | |
| SCHEMBL5462221 | 0.84 | KDR (0.44) | KDRFGFR1FLT1EGFRFLT4 | |
| SCHEMBL5411249 | 0.81 | KDR (0.62) | KDRFGFR1FLT1EGFRFLT4 | |
| Hydrochloric Acid SCHEMBL6462102 | 0.81 | KDR (0.61) | KDRFGFR1FLT1EGFRFLT4 | |
| SCHEMBL6519234 | 0.80 | FLT1 (0.55) | KDRFGFR1FLT1EGFRFLT4 | |
| SCHEMBL7736056 | 0.78 | KDR (0.67) | KDRFGFR1FLT1EGFRFLT4 | |
| SCHEMBL7738591 | 0.78 | KDR (0.61) | KDRFGFR1FLT1EGFRFLT4 | |
| SCHEMBL6477340 | 0.78 | KDR (0.55) | KDRFGFR1FLT1EGFRFLT4 | |
| Hydrochloric Acid SCHEMBL6517806 | 0.77 | FLT1 (0.50) | KDRFGFR1FLT1EGFRFLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020173646-A1 | Quinazoline derivatives and pharmaceutical compositions containing them | ZENECA LIMITED | 2002-11-21 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173646-A1 | Quinazoline derivatives and pharmaceutical compositions containing them | CNKSR1, FLT1, VEGFA | KDR 4/4885FGFR1 195/4885FLT1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.